Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Despite posting some strong earnings, the market for Sunzen Biotech Berhad's (KLSE:SUNZEN) stock hasn't moved much. We did some digging, and we found some concerning factors in the details.

See our latest analysis for Sunzen Biotech Berhad

To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Sunzen Biotech Berhad increased the number of shares on issue by 11% over the last twelve months by issuing new shares. Therefore, each share now receives a smaller portion of profit. To celebrate net income while ignoring dilution is like rejoicing because you have a single slice of a larger pizza, but ignoring the fact that the pizza is now cut into many more slices. Check out Sunzen Biotech Berhad's historical EPS growth by clicking on this link.

A Look At The Impact Of Sunzen Biotech Berhad's Dilution On Its Earnings Per Share (EPS)

Three years ago, Sunzen Biotech Berhad lost money. The good news is that profit was up 43% in the last twelve months. But EPS was less impressive, up only 49% in that time. So you can see that the dilution has had a bit of an impact on shareholders.

Changes in the share price do tend to reflect changes in earnings per share, in the long run. So it will certainly be a positive for shareholders if Sunzen Biotech Berhad can grow EPS persistently. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sunzen Biotech Berhad.

Our Take On Sunzen Biotech Berhad's Profit Performance

Each Sunzen Biotech Berhad share now gets a meaningfully smaller slice of its overall profit, due to dilution of existing shareholders. Because of this, we think that it may be that Sunzen Biotech Berhad's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 49% EPS growth in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Sunzen Biotech Berhad at this point in time. For example - Sunzen Biotech Berhad has 2 warning signs we think you should be aware of.

Today we've zoomed in on a single data point to better understand the nature of Sunzen Biotech Berhad's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.